Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Raw Materials: 2021-2023

Historic Raw Materials for Apellis Pharmaceuticals (APLS) over the last 3 years, with Dec 2023 value amounting to $32.7 million.

  • Apellis Pharmaceuticals' Raw Materials rose 23.98% to $42.1 million in Q1 2024 from the same period last year, while for Mar 2024 it was $42.1 million, marking a year-over-year increase of 23.98%. This contributed to the annual value of $32.7 million for FY2023, which is 9.64% up from last year.
  • According to the latest figures from FY2023, Apellis Pharmaceuticals' Raw Materials is $32.7 million, which was up 9.64% from $29.8 million recorded in FY2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Raw Materials peaked at $32.7 million during FY2023, and registered a low of $5.7 million during FY2021.
  • For the 3-year period, Apellis Pharmaceuticals' Raw Materials averaged around $22.8 million, with its median value being $29.8 million (2022).
  • Data for Apellis Pharmaceuticals' Raw Materials shows a peak YoY surged of 419.17% (in 2022) over the last 5 years.
  • Apellis Pharmaceuticals' Raw Materials (Yearly) stood at $5.7 million in 2021, then surged by 419.17% to $29.8 million in 2022, then rose by 9.64% to $32.7 million in 2023.